UK ad­vis­es against cov­er­ing No­var­tis' Kym­ri­ah for adults; Ex-Mast chief Bri­an Cul­ley ap­point­ed CEO at Bi­o­Time

7 years ago
News Briefing

Two Genen­tech vets re­unite at Im­mune-Onc to help steer its $33M dri­ve to the clin­ic

7 years ago
Financing

Glob­al reach: The top 25 bio­phar­ma com­pa­nies in the world

7 years ago
Special

Sil­ver­back starts to slow­ly edge out of stealth mode — but there’s still plen­ty be­ing kept un­der wraps

7 years ago
Financing

Clarus spear­heads a big, $150M raise so Galera can flip the PhI­II card on its new drug to treat ra­di­a­tion ef­fects

7 years ago
Financing

Clo­vis CEO Patrick Ma­haffy set­tles up on SEC charges of ly­ing about the ro­ci da­ta — and it won’t cost much

7 years ago
People

Cal­i­for­nia in­sur­ance com­mis­sion­er files suit against Ab­b­Vie, claims wide­spread kick­back scheme to pro­mote its ...

7 years ago
Pharma

GSK poach­es new drug de­vel­op­ment chief Chris Cor­si­co from Boehringer, di­vid­ing R&D in­to two groups

7 years ago
People

A snap­shot of up­beat PhII NASH da­ta — from a very small tri­al — trig­gers a fren­zy for Viking’s stock

7 years ago
R&D

WuXi AppTec files for pub­lic list­ing in Hong Kong four months af­ter ex­plo­sive Shang­hai IPO

7 years ago
Financing
China

As­traZeneca touts ex­tend­ed safe­ty and ef­fi­ca­cy da­ta on Fasen­ra; Vanes­sa King takes the helm at Viri­on

7 years ago
News Briefing

Unit­ed’s Mar­tine Roth­blatt en­dors­es a biotech uni­corn’s CEO and antes up for US rights to an IPF drug

7 years ago
R&D
Pharma

Servi­er shrugs off a mul­ti­mil­lion-dol­lar in­vest­ment, aban­don­ing a failed MS drug de­vel­oped by GeNeu­ro

7 years ago
R&D
Pharma

An­oth­er sci­en­tist pleads guilty for his role in a scheme to sell GSK's trade se­crets in Chi­na

7 years ago
People
China

Al­ler­gan, So­sei halt glob­al de­vel­op­ment for Alzheimer’s drug fol­low­ing tox­ic re­ac­tion in a non-hu­man pri­mate

7 years ago
R&D

No­vo Nordisk is whack­ing 400 R&D jobs, re­or­ga­niz­ing glob­al R&D ops around 4 “trans­for­ma­tion­al” units

7 years ago
R&D
Pharma

Law­mak­ers halt push for drug prices in TV ads

7 years ago
Pharma

Sen­si­tized by a se­ries of scan­dals around the world, No­var­tis spot­lights its ethics poli­cies

7 years ago
Pharma

Ar­genx buoyed by PhII tri­al re­sults; Boehringer touts a big batch of re­al-world COPD da­ta

7 years ago
News Briefing

Launch a new com­pa­ny, steer a $150M IPO and ink a big da­ta col­lab­o­ra­tion — they call it Mon­day at Vivek ...

7 years ago
Financing
Startups

Can­cer Re­search UK launch­es new Lon­don Cen­tre, in­fus­ing £14M in­to bio­ther­a­peu­tics work from lead­ing in­sti­tutes

7 years ago
R&D
Pharma

Af­ter back-to-back tri­al flops, Realm slash­es its staff, halts re­search work and pon­ders a fire sale

7 years ago
R&D

CRISPR pays to part­ner with Vi­a­Cyte on an off-the-shelf gene-edit­ing ap­proach to cur­ing di­a­betes

7 years ago
Pharma

As­traZeneca's res­pi­ra­to­ry group spells out some set­backs in its lat­est PhI­II read­out for GSK COPD ri­val PT010

7 years ago
R&D
First page Previous page 99599699799899910001001 Next page Last page
A service from the Financial Times